TARSONS319.00

Tarsons Products Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersFISCHERLAXMIDENTLFABTECHGKBMcap ₹1,697 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations296.4392.4422.5441.4
Other Income11.516.024.226.8
Total Income307.9408.4446.7468.2
Expenses
+ Cost of Materials Consumed63.080.073.079.4
+ Purchases of Stock-in-Trade16.251.049.851.8
+ Changes in Inventories2.9-1.616.117.1
+ Employee Benefit Expense44.365.475.578.9
+ Finance Costs10.119.422.523.7
+ Depreciation & Amortisation40.462.596.5103.6
+ Other Expenses70.186.990.295.0
Total Expenses247.1363.6423.7449.5
EBITDA99.8110.7117.9119.2
EBIT59.448.221.415.6
Profit
PBT before Exceptional Items60.844.823.018.7
+ Exceptional Items0.00.0-1.1-1.1
Pretax Income60.844.821.917.5
+ Current Tax18.614.96.15.0
+ Deferred Tax-0.40.21.41.5
Tax Expense18.115.07.66.4
Net Income42.629.814.311.1
+ Net Income — Continuing Ops42.629.814.311.1
+ Other Comprehensive Income0.9-1.8-9.8-3.4
Total Comprehensive Income43.628.04.57.7
Per Share
Basic EPS8.015.602.692.09
Diluted EPS8.015.602.692.09
Other Comprehensive Income — detail
+ Other Comprehensive Income-1.8-9.8-3.4
+ Items NOT to be Reclassified to P&L-9.7-0.5
+ Tax on Items NOT to be Reclassified0.20.2
+ Items to be Reclassified to P&L0.9-1.8
+ Tax on Items to be Reclassified-0.00.00.0
+ Tax on Items to be Reclassified — alt tag-0.0
Per Share — as-filed variants
Basic EPS — Continuing Operations8.015.602.692.09
Diluted EPS — Continuing Operations8.015.602.692.09
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit214.2263.0283.6293.1
Gross Margin %72.2667.0167.1366.41
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)60.844.823.018.7
− Exceptional Items (reconciliation)0.00.0-1.1-1.1
Net Income Adj (tax-effected)42.629.815.111.8
EPS Adj8.015.602.832.22
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.002.002.002.00
Paid Up Equity Capital10.610.610.610.6
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.